Open AccessSafety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
Author(s) -
Elena Verzoni,
Paolo Grassi,
Raffaele Ratta,
Monica Niger,
Filippo de Braud,
R. Valdagni,
Giuseppe Procopio
Publication year - 2016
Publication title -
therapeutic advances in medical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 49
eISSN - 1758-8359
pISSN - 1758-8340
DOI - 10.1177/1758834016656493
Subject(s) - medicine , prostate cancer , adverse effect , common terminology criteria for adverse events , concomitant , ejection fraction , abiraterone acetate , prednisone , blood pressure , stroke (engine) , cardiology , diabetes mellitus , cancer , heart failure , androgen deprivation therapy , mechanical engineering , endocrinology , engineering
We aimed to evaluate the long-term safety profile of abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) with controlled cardiovascular comorbidities or risk factors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom